共 50 条
Donepezil in Parkinson's disease dementia: A randomized, double-blind efficacy and safety study
被引:135
|作者:
Dubois, Bruno
[1
,2
]
Tolosa, Eduardo
[3
]
Katzenschlager, Regina
[4
]
Emre, Murat
[5
]
Lees, Andrew J.
[6
,7
]
Schumann, Guenther
Pourcher, Emmanuelle
[8
]
Gray, Julian
[9
]
Thomas, Gail
[10
]
Swartz, Jina
[10
]
Hsu, Timothy
[11
]
Moline, Margaret L.
[11
]
机构:
[1] Univ Paris 06, Ctr Rech, Inst Cerveau & Moelle Epiniere CRICM, UMR S975, F-75013 Paris, France
[2] Grp Hosp Pitie Salpetriere, AP HP, INSERM, U975,IMMA, F-75634 Paris, France
[3] Univ Barcelona, Ctr Invest Biomed Red Enfermedades Neurodegenerat, IDIBAPS, Neurol Serv,Hosp Clin, Barcelona, Spain
[4] Donauspital SMZ Ost, Dept Neurol, Vienna, Austria
[5] Istanbul Univ, Dept Neurol, Behav Neurol & Movement Disorders Unit, Istanbul, Turkey
[6] Reta Lila Weston Inst Neurol Studies, London, England
[7] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England
[8] Quebec Memory & Motor Skills Disorders Res Ctr, Clin St Anne, Quebec City, PQ, Canada
[9] McArthur & Associates GmbH, Basel, Switzerland
[10] Eisai Ltd, Hatfield, Herts, England
[11] Eisai Inc, Woodcliff Lake, NJ USA
关键词:
dementia;
cognition;
executive function;
cholinesterase inhibition;
ALZHEIMERS-DISEASE;
LEWY BODIES;
COGNITIVE IMPAIRMENT;
RIVASTIGMINE;
DYSFUNCTION;
PROGRESSION;
DIAGNOSIS;
D O I:
10.1002/mds.25098
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer's Disease Assessment Scalecognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function). Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms. Safety and tolerability were assessed. ADAS-cog mean changes from baseline to week 24 (end point) were not significant for donepezil in the intent-to-treat population by the predefined statistical model (difference from placebo: -1.45, P = .050, for 5 mg; -1.45, P = .076, for 10 mg). Alternative ADAS-cog analysis, removing the treatment-by-country interaction term from the model, revealed significant, dose-dependent benefit with donepezil (difference from placebo: -2.08, P = .002, for 5 mg; -3.31, P < .001, for 10 mg). The 10-mg group, but not the 5-mg group, had significantly better CIBIC+ scores compared with placebo (3.7 vs 3.9, P = .113, for 5 mg; 3.6 vs 3.9, P = .040, for 10 mg). Secondary end pointsMiniMental State Exam; DelisKaplan Executive Function System; Brief Test of Attention, representing cognitive functions particularly relevant to PDDshowed significant benefit for both donepezil doses (P = .007). There were no significant differences in ADLs or behavior. Adverse events were more common with donepezil but mostly mild/moderate in severity. Although the study did not achieve its predefined primary end points, it presents evidence suggesting that donepezil can improve cognition, executive function, and global status in PDD. Tolerability was consistent with the known safety profile of donepezil. (C) 2012 Movement Disorder Society
引用
收藏
页码:1230 / 1238
页数:9
相关论文